The AKAP8 Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-mediated polyclonal knockout population derived from the A-549 lung adenocarcinoma line. This product features targeted disruption of the AKAP8 gene, producing a heterogeneous loss-of-function model suitable for population-level analyses. The polyclonal format avoids clonal selection, capturing the diversity of editing events and mitigating clonal adaptation artifacts. Researchers can employ these cells to examine AKAP8-dependent processes in nuclear signaling, mitotic regulation, and gene expression.
The A-549 cell line originates from a lung adenocarcinoma of a 58-year-old male, exhibiting an alveolar epithelial type II phenotype with an activating KRAS mutation. This established non-small cell lung cancer model recapitulates key features of oncogenic KRAS-driven disease, making it valuable for probing tumor-associated signaling networks. The adherent cells retain near-diploid karyotype and are routinely utilized in cancer biology, drug testing, and toxicology screens.
AKAP8, or A-kinase anchoring protein 8, scaffolds the PKA RII?? subunit to the nuclear matrix and chromatin, compartmentalizing cAMP/PKA signaling to discrete subnuclear domains. This organization facilitates PKA- and CDK1/cyclin B-mediated phosphorylation of mitotic effectors, particularly histone H3 and condensin complexes, ensuring proper chromosome condensation and segregation. AKAP8 also associates with DDX5/p68 RNA helicase, SR proteins, and RNA polymerase II, linking PKA activity to mRNA splicing and transcriptional control. Its disruption consequently abrogates nuclear PKA localization, impairing phosphorylation of lamin B and other substrates, and leads to mitotic defects and altered RNA processing, underscoring its integrative role in cell division and gene regulation.
In the KRAS-mutant A-549 background, AKAP8 loss is poised to affect malignant proliferation by compromising mitotic fidelity and nuclear PKA signaling. This knockout model enables dissection of AKAP8??s contribution to lung adenocarcinoma biology, including potential interactions between AKAP8-dependent pathways and oncogenic KRAS signaling. It provides a platform to study chromatin remodeling, splicing dysregulation, and the impact on drug sensitivity in a clinically relevant NSCLC setting.
Application areas span transcriptome profiling via RNA-seq, phosphoproteomic interrogation of PKA networks, and functional rescue experiments. Representative assays include immunoblotting and RT-qPCR for validation, co-immunoprecipitation for interaction mapping, immunofluorescence for subcellular localization, and flow cytometry for cell cycle and proliferation analysis. Drug sensitivity panels can uncover synthetic vulnerabilities. This tool serves cancer biologists and signal transduction researchers exploring nuclear kinase scaffolds in lung adenocarcinoma. For further details, please contact Ascent Research.
